Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02514746
Recruitment Status : Completed
First Posted : August 4, 2015
Results First Posted : October 19, 2020
Last Update Posted : October 19, 2020
Sponsor:
Collaborator:
International Centre for Diarrhoeal Disease Research, Bangladesh
Information provided by (Responsible Party):
PATH

Brief Summary:
This study aims to understand the persistence of the Japanese encephalitis (JE) antibody response in previously vaccinated children. The proposed study will enrol Bangladeshi children who had previously participated in a lot to lot consistency study (JEV05; NCT01567865) of JE live attenuated SA 14-14-2 vaccine (CD-JEV).

Condition or disease Intervention/treatment Phase
Encephalitis, Japanese Biological: Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine Phase 4

Detailed Description:

Study participants previously immunized with CD-JEV (Clinical Trials identifier: NCT01567865, JEV05) will have serum collected three and four years after initial vaccination to assess long-term immunogenicity. Four years after receiving the initial dose of CD-JEV, eligible participants will be vaccinated with a second subcutaneous dose of CD-JEV to assess the antibody response.

Participants will be monitored for safety for 28 days following receipt of the booster dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 561 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Assessment of Long Term Immunogenicity of Japanese Encephalitis Live Attenuated SA-14-14-2 Vaccine in Previously Vaccinated Bangladeshi Children and Antibody Response and Safety to a Booster Dose
Actual Study Start Date : July 30, 2015
Actual Primary Completion Date : December 15, 2016
Actual Study Completion Date : January 12, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Live Attenuated JE SA-14-14-2 Vaccine (CD-JEV)
Participants previously vaccinated with CD-JEV will receive a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine four years after initial vaccination.
Biological: Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine
0.5 mL subcutaneous injection
Other Names:
  • CD-JEV
  • CD.JEVAX®
  • RS.JEV®




Primary Outcome Measures :
  1. Seroprotection Rate Three and Four Years After Initial Vaccination With CD-JEV [ Time Frame: 3 years after initial vaccination (Study Day 1) and 4 years after initial vaccination (Study Day 365) ]
    Seroprotection rate is defined as the percentage of participants with an anti-Japanese encephalitis (JE) neutralizing antibody titer ≥ 1:10 as measured using a 50% plaque reduction neutralization test (PRNT-50). Seroprotection was assessed at 3 and 4 years after the initial vaccination in Study JEV05, prior to participants receiving a booster vaccination in the current study.

  2. Geometric Mean Titer of Anti-JE Neutralizing Antibodies Three and Four Years After Initial Vaccination With CD-JEV [ Time Frame: 3 years after initial vaccination (Study Day 1) and 4 years after initial vaccination (Study Day 365) ]
    The geometric mean titer (GMT) of anti-JE neutralizing antibodies 3 and 4 years after initial vaccination with CD-JEV in Study JEV05 and prior to receiving the booster vaccination in the current study, measured using PRNT-50.


Secondary Outcome Measures :
  1. Seroprotection Rate 7 Days and 28 Days After Booster Dose [ Time Frame: 7 days and 28 days following booster vaccination (Study Days 372 and 393) ]
    Seroprotection rate is defined as the percentage of study participants with an anti-JE neutralizing antibody titer ≥1:10 assessed using PRNT-50.

  2. GMT of Anti-JE Neutralizing Antibodies 7 Days and 28 Days After Booster Dose [ Time Frame: 7 days and 28 days following booster vaccination (Study Days 372 and 393) ]
    Geometric mean titer of anti-JE neutralizing antibodies measured using PRNT-50.

  3. Seroconversion Rate 7 Days and 28 Days After Booster Dose [ Time Frame: 7 days and 28 days following booster vaccination (Study Days 372 and 393) ]

    Seroconversion rate is defined as the percentage of study participants with either:

    • For participants who were seronegative at Baseline (defined as anti-JE neutralizing antibody titer of < 1:10 assessed using PRNT-50 at Year 4, prior to booster vaccination): A change in serostatus from seronegative (anti-JE neutralizing antibody titer of < 1:10) to positive (anti-JE neutralizing antibody titer ≥ 1:10)
    • For participants who were seropositive at Baseline (defined as an anti-JE neutralizing antibody titer ≥1:10 assessed using PRNT-50 at Year 4, prior to booster vaccination): a 4-fold increase in anti-JE neutralizing antibody titer relative to Baseline anti-JE neutralizing antibody titer

  4. GMT Ratio of Anti-JE Neutralizing Antibody Titers Between Post-Booster and Pre-Booster Vaccination [ Time Frame: 4 years after the initial vaccination (Study Day 365, pre-booster vaccination) and 7 and 28 days following booster vaccination (Study Days 372 and 393) ]

    To evaluate the magnitude of the increase in GMTs, the GMT ratio of anti-JE neutralizing antibody titers between post-booster vaccination and pre-booster vaccination was calculated for the following:

    • GMT of anti-JE neutralizing antibodies at 7 days after booster vaccination to the Year 4, pre-booster GMT of anti-JE neutralizing antibodies
    • GMT of anti-JE neutralizing antibodies at 28 days after booster vaccination to the Year 4, pre-booster GMT of anti-JE neutralizing antibodies

  5. Number of Participants With Immediate Reactions 30 Minutes Following Booster Vaccination [ Time Frame: 30 minutes following booster vaccination (Study Day 365) ]
    The number of participants with at least one occurrence of an immediate reaction, including local, systemic, or unsolicited adverse event that occurred within 30 minutes of the booster vaccination.

  6. Number of Participants With Solicited Local Reactions Occurring Within 7 Days of Booster Vaccination [ Time Frame: From 30 minutes to 7 days following booster vaccination (Study Day 365 to 372) ]

    Participants were monitored for local reactions from 30 minutes through 7 days post booster vaccination. Local reactions (at the injection site) included the following:

    • Ecchymosis (bruising)
    • Erythema (redness)
    • Edema (swelling)
    • Induration (hardness)
    • Pain/tenderness

    Local ecchymosis, erythema, edema, and induration were graded as follows:

    • Grade 1: ≤ 2.5 cm in diameter
    • Grade 2: > 2.5 cm in diameter with < 50% surface area of extremity involved
    • Grade 3: ≥ 50% surface area of extremity involved OR ulceration OR secondary infection OR phlebitis OR sterile abscess OR drainage
    • Grade 4: potentially life-threatening consequences

    Injection site pain/tenderness were graded as follows:

    • Grade 1: causing no or minimal limitation in use of limb
    • Grade 2: causing greater than minimal limitation of use of limb
    • Grade 3: causing inability to perform usual social or functional activities
    • Grade 4: inability to perform basic self-care OR hospitalization indicated.

  7. Number of Participants With Solicited Systemic Reactions Occurring Within 7 Days of Booster Vaccination [ Time Frame: From 30 minutes to 7 days following booster vaccination (Study Day 365 to 372) ]

    Participants were monitored for systemic reactions from 30 minutes through 7 days post booster vaccination. Systemic reactions (general signs / symptoms) included the following:

    • Fever
    • Change in eating habits
    • Diarrhea
    • Sleepiness
    • Irritability
    • Unusual crying
    • Vomiting

    Fever was graded as follows:

    • Grade 1: 37.5 ℃ to 37.9 ℃
    • Grade 2: 38.0 ℃ to 38.4 ℃
    • Grade 3: 38.5 ℃ to 40.0 ℃
    • Grade 4: > 40.0 ℃

    Change in eating habits, diarrhea, sleepiness, irritability, unusual crying, vomiting were graded as follows:

    • Grade 1: causing no or minimal interference with usual social or functional activities
    • Grade 2: causing greater than minimal interference with usual social or functional activities
    • Grade 3: causing inability to perform usual social or functional activities OR hospitalization indicated
    • Grade 4: inability to perform basic self-care OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.

  8. Number of Participants With Unsolicited Adverse Events (AEs) and Serious Adverse Events (SAEs) Within 28 Days Following Booster Vaccination [ Time Frame: 28 days following booster vaccination (Study Days 365 to 393) ]

    AEs were graded for severity according to the following:

    Grade 1 (Mild): Symptoms causing no or minimal interference with usual social and functional activities

    Grade 2 (Moderate): Symptoms causing greater than minimal interference with usual social and functional activities

    Grade 3 (Severe): Symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated

    Grade 4 (Potentially life-threatening): Symptoms causing inability to perform basic self-care functions OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.

    Relationship to study vaccine was based on the Clinician's assessment.

    A serious adverse event is defined as an AE that meets 1 of the following criteria:

    • Death
    • Life-threatening
    • Requires hospitalization or prolongation of existing hospitalization
    • Results in persistent disability
    • Important medical event based on medical judgement



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   43 Months to 51 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participant in JEV05 study (NCT01567865) and received one dose of CD-JEV.
  • Resides in the Matlab or Mirpur study area.
  • At least one parent or guardian willing to provide written informed consent.

Exclusion Criteria:

  • Received a second dose of Japanese encephalitis vaccine within the past three years.
  • Received immunoglobulins and/or any blood products within 90 days prior to enrollment.
  • Been diagnosed with a primary or acquired immunodeficiency, including human immunodeficiency virus (HIV) infection within the past three years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02514746


Sponsors and Collaborators
PATH
International Centre for Diarrhoeal Disease Research, Bangladesh
Investigators
Layout table for investigator information
Principal Investigator: K Zaman, PhD, MPH, MBBS International Centre for Diarrhoeal Disease Research, Bangladesh
  Study Documents (Full-Text)

Documents provided by PATH:
Study Protocol  [PDF] March 4, 2018
Statistical Analysis Plan  [PDF] July 12, 2018

Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: PATH
ClinicalTrials.gov Identifier: NCT02514746    
Other Study ID Numbers: JEV07
PR-15036 ( Other Identifier: International Centre for Diarrhoeal Disease Research, Bangladesh )
First Posted: August 4, 2015    Key Record Dates
Results First Posted: October 19, 2020
Last Update Posted: October 19, 2020
Last Verified: August 2020
Keywords provided by PATH:
Japanese Encephalitis Vaccines
Flavivirus Infections
Additional relevant MeSH terms:
Layout table for MeSH terms
Encephalitis, Japanese
Encephalitis
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Encephalitis, Arbovirus
Encephalitis, Viral
Central Nervous System Viral Diseases
Central Nervous System Infections
Infections
Infectious Encephalitis
Arbovirus Infections
Vector Borne Diseases
Virus Diseases
RNA Virus Infections
Flavivirus Infections
Flaviviridae Infections